Zimbabwe has rejected a significant US healthcare agreement valued at $367m (272 million pounds) spanning five years over the United States' request for confidential information.
This rejection became public following a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesman later explained that the US was seeking health data for scientific study and profit while was not willing to share the benefits from any future vaccines.
"We will now turn to the difficult and regrettable task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further talks to secure a deal agreeable to all parties so the country's vital HIV programme can proceed.
Wider Background
Zimbabwe's decision follows a comparable situation in Kenya, where a court suspended a similar deal with the US following concerns were filed about the safety of citizens' medical information.
After returning to office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had managed aid for the American government, but Trump argued its expenditure was "wasteful" and his government was seeking government-to-government agreements to boost transparency and accountability.
Based on statements, Sixteen African countries have to date signed these new agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy through US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data over an extended period, with no equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for medical research without any certainty that the end products would be accessible to our people if a new pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining frameworks previously set up via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This framework is intended to guarantee that when a country provides its samples, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome further discussions with our American counterparts on how future collaboration might be designed in a way that respects the sovereignty and dignity of both nations."
Medical Community Response
Medical experts said it understood the government's concerns, but suggested that negotiations need to persist given that much of the country's Aids initiatives relied on external financing.
"In cases where specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," the group said.
This impasse emphasises the complex tensions between accepting vital international aid and safeguarding national sovereignty in an increasingly data-driven world.